BriaCell 2024 SABCS Spotlight Poster To Showcase Overall Survival Data Across All Patient Subtypes In Metastatic Breast Cancer; Median Overall Survival Of 13.4 Months Exceeds Historical Controls. Phase 2 Final Median Overall Survival Calculation Is Pending, As Many Patients Remain Alive

Benzinga · 11/26 13:02
  • SABCS® "Spotlight" poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast cancer patient subtypes
  • Median overall survival of 13.4 months exceeds historical controls. Phase 2 final median overall survival calculation is pending, as many patients remain alive
  • Potential identification of biomarkers to predict response
  • Five poster presentations to feature increased presence of cancer fighting CD8+ "killer" T cell in metastatic breast cancer tumors, response in central nervous system (CNS) metastases and additional Bria-IMT™ clinical data from the Phase 2 trial of Bria-IMT™ + immune check point inhibitor in metastatic breast cancer
  • Collaboration with the Medical College of Wisconsin will investigate use of Bria-IMT™ + CPI in any cancer patient with central nervous system (CNS) metastases

     

PHILADELPHIA and VANCOUVER, British Columbia, Nov. 26, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, will be highlighting its positive overall survival and clinical benefit data in metastatic breast cancer (MBC) patients including those with CNS metastasis (not shown on the abstracts) who were treated with the Bria-IMT™ plus immune checkpoint inhibitor (CPI) combination in its "Spotlight" poster presentation session, at the 2024 San Antonio Breast Cancer Symposium® (SABCS®) held at Henry B. Gonzalez Convention Center, San Antonio, TX.